

NCT02874092 Raw comparison:

Summary:
CHIA has 22 criteria while your personal folder has 28 criteria
Total found criteria: 20/22
Total not Found: 2/22
Total Extra: 6
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ OA cohort Diagnosis of osteoarthritis made by      │ Diagnosis of osteoarthritis made by physician      │
│ physician                                          │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of sensitivity to study medications or any │ History of sensitivity to study medications or any │
│ of their excipients                                │ of their excipients                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current treatment with antiplatelet therapy        │ Current treatment with antiplatelet therapy        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Absolute indication for anti-platelet therapy      │ Absolute indication for anti-platelet therapy      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Need for chronic oral anticoagulant therapy        │ Need for chronic oral anticoagulant therapy        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe hepatic impairment (eg ascites and/or       │ Severe hepatic impairment (eg ascites and/or       │
│ clinical signs of coagulopathy)                    │ clinical signs of coagulopathy)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal failure (eGFR <30 or requiring dialysis)     │ Renal failure (eGFR \<30 or requiring dialysis)    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A known bleeding diathesis hemostatic or           │ A known bleeding diathesis hemostatic or           │
│ coagulation disorder or prior major bleeding       │ coagulation disorder or prior major bleeding       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior stroke                                       │ Prior stroke                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active pathological bleeding                       │ Active pathological bleeding                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of intracranial haemorrhage                │ History of intracranial haemorrhage                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy <12 months based on investigator's │ Life expectancy \<12 months based on               │
│ judgement                                          │ investigator's judgement                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients considered to be at risk of bradycardic   │ Patients considered to be at risk of bradycardic   │
│ events (e g known sick sinus syndrome or second or │ events (e g known sick sinus syndrome or second or │
│ third degree atrioventricular [AV)] block) unless  │ third degree atrioventricular \[AV)\] block)       │
│ already treated with a permanent pacemaker         │ unless already treated with a permanent pacemaker  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Anemia (hematocrit < 27%)                          │ Anemia (hematocrit \< 27%)                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count < 100 000/ml                        │ Platelet count \< 100 000/ml                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant use of strong CYP 3A inhibitors or     │ Concomitant use of strong CYP 3A inhibitors or     │
│ inducers                                           │ inducers                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of thrombocytopenia or neutropenia         │ History of thrombocytopenia or neutropenia         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or nursing women or females with a        │ Pregnant or nursing women or females with a        │
│ positive pregnancy test at screening               │ positive pregnancy test at screening               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of child bearing potential not using       │ Females of child bearing potential not using       │
│ acceptable method of birth control prior to or     │ acceptable method of birth control prior to or     │
│ during study                                       │ during study                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concern for inability of the patient to comply     │ Concern for inability of the patient to comply     │
│ with study procedures and/or follow up (eg alcohol │ with study procedures and/or follow up (eg alcohol │
│ or drug abuse)                                     │ or drug abuse)                                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                 │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ RA cohort Receiving MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks Have a DAS28 of │
│ 3 2 or higher (The level of disease activity is considered to be low if the DAS28 is 3 2 or less)   │
│ (Prevoo et al 1995)                                                                                 │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ RA cohort Previous intolerance to MTX                                                               │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ RA cohort                                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Receiving MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ OA cohort                                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Previous intolerance to MTX                                                                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Have a DAS28 of 3 2 or higher (The level of disease activity is considered to be low if the DAS28 is │
│ 3 2 or less) (Prevoo et al 1995)                                                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛